More than 20 million people in Germany suffer from chronic pain, with back pain being the most common form. Physiotherapy doesn't always help, long-term opioid medications create dependence, and brain stimulation works in only some patients. One of the main reasons for these failures: Current treatments target the same brain region in all patients, even though pain processing in the brain varies greatly between individuals. A study running since June 2026 at LMU Hospital Munich aims to change that.
What is neuromodulation?
Chronic pain is not just body damage. When a back problem like a herniated disc is present, the tissue often heals in many cases, but pain persists. This happens because the brain changes its own processing structure during chronic pain: Neural pathways that relay pain signals become more sensitive. What began as an alarm signal becomes an independent disorder.
Neuromodulation is the umbrella term for procedures that intervene in exactly these processing pathways without surgical access. Transcranial magnetic stimulation (TMS) uses magnetic fields, transcranial direct current stimulation (tDCS) uses weak electrical current to activate or inhibit brain regions. Both are already clinically approved, for example for treatment-resistant depression. For chronic pain, however, they show mixed results, which researchers have attributed for years to the standardized target regions: All patients are stimulated at the same location regardless of how their brain actually represents pain.
How focused ultrasound works
Focused ultrasound fundamentally differs from the diagnostic procedure familiar to pregnant women. Small transducers placed on the scalp bundle sound waves so they meet at a point in brain tissue with high energy. Precision is in the millimeter range. The target area warms up or experiences pressure changes and stresses that alter neural activity without damaging surrounding tissue.
Clinically, the procedure is not new in Germany: University Hospital Zurich (USZ) and other centers already use MRI-guided focused ultrasound for essential tremor and certain Parkinson's forms where deep brain stimulation is not an option. USZ reports significant improvement in most treated patients with essential tremor. The procedure has rarely been transferred to pain therapy, especially on a personalized basis. In Germany, the technology is available at five total locations.
What makes the NeuroPain project different
The NeuroPain project at LMU Hospital, led by psychologist Dr. Enrico Schulz, biologist Veronica Meedt (M.Sc.) and psychologist Dr. Daniel Keeser from the Radiology and Psychiatry clinics, implements a two-stage approach not previously clinically tested in this combination.
In the first step, participants with chronic back pain undergo multiple MRI scans while rating their pain intensity in real time. Through functional magnetic resonance imaging (fMRI), the team can identify which brain region correlates most strongly with pain experience in that individual. This region is individual: Psychologist Schulz emphasized in project communication that pain can now be mapped individually in the brain for each person and treated accordingly.
In the second step, this exact target region is modulated with focused ultrasound. The procedure is non-invasive; patients need no anesthesia and no hospital stay. Afterward, researchers measure whether pain intensity decreases. The project initiators call the approach unprecedented in pain research in this form.
Open questions until clinical application
The study has been running since June 2026 and is still in the recruitment phase. Concrete results will be available at the earliest in the course of 2027, once sufficient participants have completed the full two-stage treatment. Several questions remain open, which the project team themselves identify: How long does an effect last and does it need refreshing? Does the individual target region in the brain change over time? And can the procedure be extended to other pain forms, such as headaches or neuropathic pain after nerve injury?
The technical hurdle is also real: Focused ultrasound for therapeutic purposes is currently available at five locations in Germany, MRI scanners with sufficient field strength for functional measurements are complex and costly. The path from a clinical pilot study to broad care would, even with positive results, be a process taking several years, involving approval, health insurance reimbursement, and training of specialists.
This doesn't change the fact that the NeuroPain project's methodological approach has fundamental significance for pain research: If proof succeeds that individual fMRI mapping reliably identifies the correct target region, it also changes the logic of other neuromodulation procedures like TMS and tDCS. The core problem of standardization could then be approached fundamentally differently, regardless of which stimulation technology is ultimately used.
